Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1194186 | 0.86 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL6908991 | 0.85 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL29212188 | 0.80 | LMNA (0.74) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| Bromide SCHEMBL1193914 | 0.76 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL6230315 | 0.75 | ALDH1A1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL1578277 | 0.74 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL11424416 | 0.74 | NPC1 (0.93) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL445528 | 0.72 | LMNA (0.70) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL11433155 | 0.72 | NPC1 (0.93) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL30206692 | 0.72 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624178-B2 | Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-09-23 | — | — | US | claimed |